Home / Products / Formulations / Svizera Healthcare / Ace / Utergin
 

UTERGIN:

 
 
 
   
   
   
 
 


 
   
 
     
     
 
  Composition
   
  Each 1 ml of UTERGIN Injection contains:
  Methylergometrine maleate.....0.2 mg
   
  Each tablet of UTERGIN contains:
  Methylergometrine maleate.....0.125 mg
   
   
  Therapeutic Indications & Usage
   
  UTERGIN is indicated for routine management after delivery of the placenta; postpartum atony and hemorrhage; subinvolution.
   
   
  Contraindications
   
  UTERGIN is contraindicated in hypertension, toxemia, pregnancy and hypersensitivity to its ingredients. UTERGIN Injection is not for intra-arterial and periarterial routes of administration.
   
   
  Precautions
   
  UTERGIN must be advocated with caution in presence of sepsis, obliterative vascular disease, hepatic or renal involvement, during the second stage of labor. The necessity for manual removal of a retained placenta should occur only rarely with proper technique and adequate allowance of time for its spontaneous separation.
   
   
  Warnings
   
  UTERGIN Injection is not advocated as intravenous (IV) routinely because of the possibility of inducing severe hypertensive and cardiovascular accidents. If IV administration is deemed essential, UTERGIN Injection must be given slowly over a period of no less than 60 seconds with careful monitoring of blood pressure.
   
  Caution needs to be exercised whilst administering UTERGIN during lactation; recommended dose is 0.2 mg 3-4 times daily so as to minimize the amount of methylergometrine maleate appearing in breast milk.
   
  Methylergometrine maleate (UTERGIN) must be coadministered with caution along with macrolides antibiotics, HIV protease or reverse transcriptase inhibitors, azole antifungals, saquinavir, nefazodone, fluconazole, fluoxetine, fluvoxamine, zileuton, clotrimazole, other vasoconstrictors or ergot alkaloids.
   
   
  Adverse Reactions
   
  The most common adverse effect with methylergometrine maleate (UTERGIN) is hypertension associated with seizure and / or headache; hypotension can also occur. Occasionally nausea and vomiting are associated with its use. Rarely, methylergometrine maleate (UTERGIN) can cause hypersensitivity reactions, acute myocardial infarction, transient chest pain, dyspnea, hematuria, thombophlebitis, water intoxication, hallucinations, leg cramps, dizziness, tinnitus, nasal congestion, diarrhea, diaphoresis, palpitations and foul taste. Anaphylaxis can be a possibility due to UTERGIN Injection administration.
   
   
  Drug Interactions
   
  Methylergometrine maleate (UTERGIN) can interact with macrolide antibiotics, HIV protease or reverse transcriptase inhibitors, azole antifungals, saquinavir, nefazodone, fluconazole, fluoxetine, fluvoxamine, zileuton and clotrimazole. UTERGIN is to be used concurrently with other vasoconstrictors or ergot alkaloids.
   
   
  Recommended Dosage & Administration
   
  UTERGIN Injection
  0.2 mg (1 ml) UTERGIN intramuscular (IM) or slow IV after delivery of the anterior shoulder, after delivery of the placenta, or during puerperium; may be repeated as required, at intervals of 2-4 hours.
   
  UTERGIN Tablet
  1 UTERGIN Tab 3-4 times daily in the puerperium for maximum of 1 week.
   
   
  Presentations
   
  UTERGIN Injections: 1 ml ampoules.
UTERGIN Tablets: Blisters of 10s.
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
 
 
   
 
         
 
"Maneesh" Pharmaceuticals   |  Manufacturing Excellence  |   International Presence  |  Products
"Maneesh" for Doctors  |  Our Team  |  For the Patients  
Contact Us  |  Feedback  |  Site Map  | Search Maneesh